Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company, will participate in the BIO International Convention from June 16-19, 2025, in Boston, MA. The company, known for its focus on developing novel immuno-oncology therapeutics using its ADAPTIR® and ADAPTIR-FLEX® platform technologies, will be represented by Michelle N. Nelson, Ph.D., Director of Immunobiology, and SoYoung Kwon, SVP, General Counsel and Head of Business Development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1039187) on June 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.